TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.
Chimeric Therapeutics Ltd. announced the results of its Annual General Meeting, where all resolutions were conducted via poll. A significant outcome was the ‘first strike’ against the Remuneration Report under the Corporations Act, indicating shareholder dissatisfaction with executive pay. Additionally, Paul Hopper retired as Executive Chairman, with Phillip Hains appointed as Acting Chair until a new Chair is announced. The meeting also saw the election of Professor Henry Miles Prince as a Director and approval for issuing incentive options to him, while similar options for Paul Hopper were not approved. These developments may impact the company’s governance and strategic direction.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is primarily engaged in advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies, which are designed to harness the immune system to target and destroy cancer cells.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.11M
See more data about CHM stock on TipRanks’ Stock Analysis page.